(-)-Epigallocatechin gallate derivatives for inhibiting proteasome

Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/5764

Title:	(-)-Epigallocatechin gallate derivatives for inhibiting proteasome
Authors:	Chan, TH Lam, WH Chow, LMC Dou, QP Kuhn, DJ Kazi, A Wan, SB Landis-Piwowar, KR
Issue Date:	5-Jun-2012
Source:	US Patent 8,193,377 B2. Washington, DC: US Patent and Trademark Office, 2012.
Abstract:	(-)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (-)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formulae below, wherein R₁₁, R₁₂, R₁₃, R₂₁, R₂₂, R₂, R₃, and R₄ are each independently selected from the group consisting of --H, and C₁ to C₁₀ acyloxyl group; and R₅ is selected from the group consisting of --H, C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₃-C₇-cycloalkyl, phenyl, benzyl and C₃-C₇-cycloalkenyl, whereas each of the last mentioned 7 groups can be substituted with any combination of one to six halogen atoms; at least one of R₁₁, R₁₂, R₁₃, R₂₁, R₂₂, R₂, R₃ and R₄ is --H, which were found to be more potent than their non-protected counterparts, which can be used as proteasome inhibitors to reduce tumor cell growth.
Rights:	Assignee: The Hong Kong Polytechnic University. Assignee: Wayne State University. Assignee: University of South Florida.
Appears in Collections:	Patent

File	Description	Size	Format
us8193377b2.pdf		2.06 MB	Adobe PDF	View/Open

Show full item record

73

Last Week
2

Last month

Citations as of Jun 4, 2023

32

Citations as of Jun 4, 2023

Check